FIG 1.

Evaluating the influence of therapy initiation on EIDD-1931 antiviral activity. A549 cells that stably expressed ACE2 were mixed with SARS-CoV-2 (MOI = 10 to 5) and inoculated into the hollow fiber infection model (HFIM). EIDD-1931 therapy (tx) was administered into hollow fiber (HF) cartridges at concentrations equivalent to 0.146 μg/mL (A), 0.324 μg/mL (B), and 3.5 μg/mL (C) beginning at 0 h (tx at 0 h), 24 h (tx at 24 h), 48 h (tx at 48 h), or 72 h (tx at 72 h) postinfection. HF cartridges were sampled daily, and the infectious viral burden was quantified by plaque assay on Vero E6 cells. Data points are reported in log₁₀ PFU per mL and represent the mean of two biological replicates ± one standard deviation. The dashed line corresponds to the plaque assay limit of detection (2 log₁₀ PFU/mL). Two independent studies were conducted.